Population-based outcomes of patients (pt) with early-stage HER2-positive breast cancer treated with adjuvant trastuzumab (T).

被引：0
|
作者：
Noonan, Krista
McCarthy, Joy S.
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
[2] Dr H Bliss Murphy Canc Ctr, St John, NF, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11079
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Outcomes of HER2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients
    Zurawska, U.
    Baribeau, D. A.
    Giilck, S.
    Victor, C.
    Gandhi, S.
    Florescu, A.
    Verma, S.
    CURRENT ONCOLOGY, 2013, 20 (06) : E539 - E545
  • [2] Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab
    Tonyali, Onder
    Coskun, Ugur
    Sener, Nur
    Inanc, Mevlude
    Akman, Tulay
    Ulas, Arife
    Yazilitas, Dogan
    Bal, Oznur
    Kucukoner, Mehmet
    Ozdemir, Nuriye Yildirim
    Demirci, Umut
    Gunaydin, Yusuf
    Yildiz, Ramazan
    Karaca, Halit
    Unal, Olcun Umit
    Gumus, Mahmut
    Benekli, Mustafa
    Buyukberber, Suleyman
    ONKOLOGIE, 2013, 36 (10): : 554 - 558
  • [3] Impact of delaying initiation of adjuvant chemotherapy and trastuzumab in patients with early-stage HER2-positive breast cancer.
    Fried, Geordeta
    Shachar, Shlomit Strulov
    Anani, Sapir
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
    Ratti, Riccardo
    Coccorullo, Zaira
    Guarneri, Domenico
    Colloca, Giuseppe
    Venturino, Antonella
    Addamo, Gianfranco
    Campora, Elisabetta
    ANNALS OF ONCOLOGY, 2009, 20
  • [5] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
    Ratti, R.
    Coccorullo, Z.
    Guarneri, D.
    Colloca, G.
    Addamo, G.
    Venturino, A.
    Campora, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 45 - 45
  • [6] Spotlight on trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, Greg L.
    Keam, Susan J.
    BIODRUGS, 2006, 20 (04) : 259 - 262
  • [7] Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer
    Greg L. Plosker
    Susan J. Keam
    BioDrugs, 2006, 20 : 259 - 262
  • [8] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [9] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [10] Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study
    Monica Tang
    Andrea L. Schaffer
    Belinda E. Kiely
    Benjamin Daniels
    Chee K. Lee
    Robert J. Simes
    Sallie-Anne Pearson
    Breast Cancer Research and Treatment, 2021, 187 : 893 - 902
12345